Active ingredientAzasetron HClCat. No. P-A231-001CAS 123040-16-4Family · Pharmaceutical analytical standards
Azasetron
A serotonin 5-HT3 receptor antagonist antiemetic, first marketed in Japan in the 1990s to prevent nausea and vomiting caused by cancer chemotherapy, such as cisplatin-based regimens. This family brings together the active ingredient, nitrosamines and other impurities.
Did you know?Only one of its two mirror-image forms, the R-enantiomer named arazasetron, has been studied against hearing loss, such as that caused by platinum-based chemotherapy.
Go to the active ingredient →Active ingredientAzasetron HClCat. No. P-A231-001CAS 123040-16-4
Active ingredientAzasetronCat. No. P-A231-002CAS 123040-69-7
NitrosamineN-Nitroso AzasetronCat. No. P-A231-003
ImpurityAzasetron IntermediateCat. No. P-A231-004CAS 123040-79-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.